Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497–506 (2020).
Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795–807 (2020).
Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 383, 1813–1826 (2020).
Misset, B. et al. Convalescent plasma for Covid-19-induced ARDS in mechanically ventilated patients. N. Engl. J. Med. 389, 1590–1600 (2023).
O’Halloran, J. A. et al. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: A randomized clinical trial. Jama 330, 328–339 (2023).
Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704. https://doi.org/10.1056/NEJMoa2021436 (2021).
Diamond, M. S. & Kanneganti, T.-D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 23, 165–176 (2022).
Liu, B. M., Martins, T. B., Peterson, L. K. & Hill, H. R. Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review. Cytokine 142, 155478 (2021).
Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255–2273 (2020).
Zheng, Z. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 81, e16–e25 (2020).
Kanai, M. et al. A second update on mapping the human genetic architecture of COVID-19. Nature 621, E7–E26 (2023).
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
Zhang, Q., Bastard, P., COVID Human Genetic Effort, Cobat, A. & Casanova, J.-L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603, 587–598 (2022).
Severe Covid-19 GWAS Group et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med. 383, 1522–1534 (2020).
Downes, D. J. et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat. Genet. 53, 1606–1615 (2021).
Wu, B.-B., Gu, D.-Z., Yu, J.-N., Yang, J. & Shen, W.-Q. Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 84, 104485 (2020).
Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164–171 (2013).
Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
O’Brien, T. R., Prokunina-Olsson, L. & Donnelly, R. P. IFN-λ4: the paradoxical new member of the interferon lambda family. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 34, 829–838 (2014).
Rugwizangoga, B. et al. IFNL4 genotypes predict clearance of RNA viruses in Rwandan children with upper respiratory tract infections. Front Cell Infect. Microbiol. 9, 340 (2019).
Broggi, A., Granucci, F. & Zanoni, I. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J. Exp. Med. 217, e20190295 (2020).
Saponi-Cortes, J. M. R. et al. IFNL4 genetic variant can predispose to COVID-19. Sci. Rep. 11, 21185 (2021).
Agwa, S. H. A. et al. Association between Interferon-Lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients. Genes Basel 12, 830 (2021).
Zahid, W. et al. Association of interferon Lambda 3 and 4 gene SNPs and their expression with COVID-19 disease severity: A cross-sectional study. Infect Drug Resist. 16, 6619–6628 (2023).
Rahimi, P. et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol. J. 18, 221 (2021).
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74. https://doi.org/10.1038/nature15393 (2015).
Lee, C. & Choi, W. J. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. Arch. Pharm. Res. 44, 99–116 (2021).
Husain-Syed, F., Slutsky, A. S. & Ronco, C. Lung-kidney cross-talk in the critically ill patient. Am. J. Respir. Crit. Care Med. 194, 402–414 (2016).
Mayerhöfer, T., Perschinka, F. & Joannidis, M. Akute Nierenschädigung und COVID-19: Pulmorenaler crosstalk unter massiver inflammation. Med. Klin. Intensivmed. Notfallmedizin 117, 342–348 (2022).
Alsaedi, S. B., Mineta, K., Gao, X. & Gojobori, T. Computational network analysis of host genetic risk variants of severe COVID-19. Hum. Genomics 17, 17 (2023).
Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).
Prokunina-Olsson, L. et al. COVID-19 and emerging viral infections: The case for interferon lambda. J. Exp. Med. 217, e20200653 (2020).
Liu, Y.-G. et al. Interferon lambda in respiratory viral infection: Immunomodulatory functions and antiviral effects in epithelium. Front. Immunol. 15, 1338096 (2024).
Read, S. A. et al. Macrophage coordination of the interferon lambda immune response. Front. Immunol. 10, 2674 (2019).
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P. & Shoenfeld, Y. The hyperferritinemic syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 11, 185 (2013).
Ruscitti, P. et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front. Immunol. 11, 1130 (2020).
Molina, G. et al. Hemophagocytic lymphohistiocytosis following COVID-19 infection. Cureus 15, e34307 (2023).
Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585–593 (2022).
Bellmann-Weiler, R. et al. Neopterin predicts disease severity in hospitalized patients with COVID-19. Open Forum Infect. Dis. 8, ofaa521 (2021).
Lee, M. J. & Blish, C. A. Defining the role of natural killer cells in COVID-19. Nat. Immunol. 24, 1628–1638 (2023).
Petta, S. et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin. Gastroenterol. Hepatol. 11, 311-317.e1 (2013).
Duca, A. M. et al. CC genotype at rs12979860 of IL28B is associated with lower risk of new-onset diabetes after transplantation in adult patients with liver transplantation for hepatitis C cirrhosis. Transplant. Proc. 46, 3114–3116 (2014).
Pan, H. et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. The Lancet 399, 1941–1953 (2022).
Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: A double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 1365–1376 (2021).
Monk, P. D. et al. Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study. ERJ Open Res. https://doi.org/10.1183/23120541.00605-2022 (2023).
Reis, G. et al. Early treatment with pegylated interferon lambda for Covid-19. N. Engl. J. Med. 388, 518–528 (2023).
Amodio, E. et al. SARS-CoV-2 viral load, IFNλ polymorphisms and the course of COVID-19: An observational study. J. Clin. Med. 9, 3315 (2020).
Ren, H. et al. Association of genetic polymorphisms with COVID-19 infection and outcomes: An updated meta-analysis based on 62 studies. Heliyon 10, e23662 (2024).
Mayerhöfer, T. et al. Incidence, risk factors and outcome of acute kidney injury in critically ill COVID-19 patients in Tyrol, Austria: A prospective multicenter registry study. J. Nephrol. https://doi.org/10.1007/s40620-023-01760-3 (2023).
Mayerhöfer, T. et al. Changes in characteristics and outcomes of critically ill COVID-19 patients in Tyrol (Austria) over 1 year. Wien. Klin. Wochenschr. 133, 1237–1247 (2021).
Graziadei, I. W. et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 18, 671–679 (2012).
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
